Lunch & Learn: Acquired LQT
Lunch & Learn: Acquired LQT
Tuesday, October 15 at 10:00 am PT | 1:00 pm ET
The Presenter
Dan Roden is a clinician-scientist whose research program studies how genetic variation affects human disease susceptibility, and his special interests are pharmacogenetics, and the genetic determinants of abnormal heart rhythms, especially those induced by drugs. After serving as chief of the division of Clinical Pharmacology for 12 years, he was tasked in 2006 with leading Vanderbilt’s efforts in Personalized Medicine. Under his leadership, Vanderbilt has become internationally-recognized for cutting edge programs in this area, including the large biobank BioVU and the preemptive pharmacogenetic program PREDICT. He served as Principal Investigator for the Vanderbilt site of the Pharmacogenomics Research Network (2001-2021), and currently serves as co-PI for the Vanderbilt site of the NIH’s Electronic Medical Records and Genomics (eMERGE) network (2007-2025) and the genomic Learning Healthcare System (2025-2030) network, and the Data and Research Center for the US NIH All of Us program.
Dan M Roden, MD
Professor of Medicine, Pharmacology, and Biomedical Informatics
Senior Vice-President for Personalized Medicine
Vanderbilt University Medical Center
Description
Drugs have many potential side effects. One of considerable importance is drug-induced Long QT syndrome (diLQTS), a cardiac rhythm abnormality that can lead to loss of consciousness or sudden death. Dozens of commonly prescribed medications can lead to drug-induced Long QT syndrome (diLQTS) and serious cardiac arrhythmias. The problem has become increasingly well-recognized as more QT prolonging drugs have entered the market.
In this webinar, physicians and healthcare providers can hear from an internationally-recognized expert and learn:
What drugs cause QT prolongation.
How to identify patients at particular risk.
How to monitor and protect patients taking a QT prolonging drug.